Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4

Autor: Jiansong Luo, Francesco De Pascali, G. Wendell Richmond, Amer M. Khojah, Jeffrey L. Benovic
Jazyk: angličtina
Rok vydání: 2021
Předmět:
WT
wild type

G-CSF
granulocyte colony stimulating factor

Receptors
CXCR4

pepducin
Primary Immunodeficiency Diseases
PBS
phosphate-buffered saline

Ser
serine

fs
frame shift

Biochemistry
DMEM
Dulbecco’s modified Eagle’s medium

HBSS
Hank’s buffered saline solution

ERK
extracellular signal-regulated kinase

FBS
fetal bovine serum

PKC
protein kinase C

cell signaling
endocytosis
Humans
pS
phosphoserine

BRET
bioluminescence resonance energy transfer

Molecular Biology
beta-Arrestins
GPCR
G-protein-coupled receptor

extracellular-signal-regulated kinase (ERK)
chemokine
chemokine receptor
Cell Biology
ELISA
enzyme-linked immunosorbent assay

Bis I
bisindolylmaleimide I

G-protein-coupled receptor (GPCR)
Chemokine CXCL12
protein phosphorylation
TBS
Tris-buffered saline

beta-Arrestin 1
protein degradation
TBST
Tris-buffered saline with Tween

AIP4
atrophin-1-interacting protein 4

Warts
GRK
G-protein-coupled receptor kinase

Research Article
WBC
white blood cell
Zdroj: The Journal of Biological Chemistry
ISSN: 1083-351X
0021-9258
Popis: WHIM syndrome is a rare immunodeficiency disorder that is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. While several gain-of-function mutations that lead to C-terminal truncations, frame shifts and point mutations in the chemokine receptor CXCR4 have been identified in WHIM syndrome patients, the functional effect of these mutations are not fully understood. Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 (S339fs5) and compare the properties of S339fs5 with wild-type CXCR4 and a previously identified WHIM syndrome mutant, R334X. The S339fs5 and R334X mutants exhibited significantly increased signaling compared to wild-type CXCR4 including agonist-promoted calcium flux and extracellular-signal-regulated kinase activation. This increase is at least partially due to a significant decrease in agonist-promoted phosphorylation, β-arrestin binding, and endocytosis of S339fs5 and R334X compared with wild-type CXCR4. Interestingly, there were also significant differences in receptor degradation, with S339fs5 having a very high basal level of degradation compared with that of R334X and wild-type CXCR4. In contrast to wild-type CXCR4, both R334X and S339fs5 were largely insensitive to CXCL12-promoted degradation. Moreover, while basal and agonist-promoted degradation of wild-type CXCR4 was effectively inhibited by the CXCR4 antagonist TE-14016, this had no effect on the degradation of the WHIM mutants. Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, which promotes enhanced signaling, reduced phosphorylation, β-arrestin binding and endocytosis, and a very high basal rate of degradation that is not protected by antagonist treatment.
Databáze: OpenAIRE